Ranibizumab leading the anti-VEGF evolution

Article

Considerations and new perspectives in anti-VEGF therapy.

Related Content

Corneal refractive surgery for presbyopia: why ZEISS PRESBYOND was our preferred solution

September 1st 2023

Updates From Angiogenesis-2022

February 11th 2022

iCare HOME tonometers optimize patient care

June 1st 2023

Updates from ASRS 2021

October 28th 2021

Cataract surgery in Cambodia – Achieving quality outcomes in a challenging setting with the CT LUCIA 621P

January 25th 2023

Self-tonometry provides invaluable insights into IOP fluctuations

December 1st 2022

Corneal refractive surgery for presbyopia: why ZEISS PRESBYOND was our preferred solution

September 1st 2023

Updates From Angiogenesis-2022

February 11th 2022

iCare HOME tonometers optimize patient care

June 1st 2023

Updates from ASRS 2021

October 28th 2021

Cataract surgery in Cambodia – Achieving quality outcomes in a challenging setting with the CT LUCIA 621P

January 25th 2023

Self-tonometry provides invaluable insights into IOP fluctuations

December 1st 2022

Corneal refractive surgery for presbyopia: why ZEISS PRESBYOND was our preferred solution

September 1st 2023

Updates From Angiogenesis-2022

February 11th 2022

iCare HOME tonometers optimize patient care

June 1st 2023

Updates from ASRS 2021

October 28th 2021

Cataract surgery in Cambodia – Achieving quality outcomes in a challenging setting with the CT LUCIA 621P

January 25th 2023

Self-tonometry provides invaluable insights into IOP fluctuations

December 1st 2022
© 2023 MJH Life Sciences

All rights reserved.